[ALXA] Alexza Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 20.88 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.94 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ALXA

Refresh chart

Description: Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. The company?s product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Its lead product, ADASUVE (Staccato loxapine) inhalation powder for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The company?s product candidate in development, AZ-002 (Staccato alprazolam), is indicated for the treatment of acute repetitive seizures. It has strategic collaborations with Grupo Ferrer Internacional S.A. and Teva Pharmaceuticals USA, Inc. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was inc

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding21.75 M EPS-1.38 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -52.49% Sales Growth - Q/Q-51.51% P/E-0.68
P/E To EPS Growth P/S5.09 P/BV-0.4 Price/Cash Per Share0.93
Price/Free Cash Flow-0.48 ROA-61.16% ROE51.1% ROI-94.2%
Current Ratio3.31 Quick Ratio3.01 Long Term Debt/Equity3.37 Debt Ratio-0.16
Gross Margin-345.88% Operating Margin-1016% Net Profit Margin-643.93% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities530 K Cash From Investing Activities8.1 M Cash From Operating Activities-12.73 M Gross Profit-5.44 M
Net Profit-400 K Operating Profit-13 M Total Assets43.17 M Total Current Assets27.26 M
Total Current Liabilities8.24 M Total Debt64.16 M Total Liabilities94.84 M Total Revenue700 K
Technical Data
High 52 week0.97 Low 52 week0.45 Last close0.94 Last change0%
RSI Average true range Beta1.18 Volume
Simple moving average 20 days-0% Simple moving average 50 days0% Simple moving average 200 days-0.03%
Performance Data
Performance Week0% Performance Month0% Performance Quart0% Performance Half0%
Performance Year88% Performance Year-to-date0% Volatility daily0% Volatility weekly0%
Volatility monthly0% Volatility yearly0% Relative Volume0% Average Volume
New High New Low

News

2016-07-01 16:31:05 | Delisting of Securities of Alexza Pharmaceuticals, Inc., MOKO Social Media Ltd., Hercules Offshore, Inc., FreeSeas Inc., and Pacific Sunwear of California, Inc. from The Nasdaq Stock Market

2016-07-01 16:21:04 | Delisting of Securities of Alexza Pharmaceuticals, Inc. from The Nasdaq Stock Market

2016-06-22 13:04:25 | ALEXZA PHARMACEUTICALS INC. Financials

2016-06-21 08:55:20 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisti

2016-06-21 08:39:03 | Alexza Pharmaceuticals Acquired by Ferrer

2016-06-21 08:00:00 | Alexza Pharmaceuticals Acquired by Ferrer

2016-06-16 16:10:29 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

2016-06-01 12:51:10 | Alexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016

2016-05-16 22:10:00 | INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm for Additional Information

2016-05-16 13:01:00 | ALEXZA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Ferrer Pharma, Inc. May be Unfair to Shareholders

2016-05-13 23:15:00 | SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Alexza Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information

2016-05-13 16:04:25 | ALEXZA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report

2016-05-13 10:59:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Alexza Pharmaceuticals, Inc. to Ferrer Pharma, Inc. - ALXA

2016-05-12 22:15:00 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Alexza Pharmaceuticals, Inc. -ALXA

2016-05-11 17:17:03 | Alexza Reports 2016 First Quarter Financial Results

2016-05-11 17:10:02 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a

2016-05-11 17:00:00 | Alexza Reports 2016 First Quarter Financial Results

2016-05-10 15:59:07 | Why is Alexza Pharmaceuticals ALXA Stock Soaring Today?

2016-05-10 08:48:07 | Alexza to Cancel 2016 First Quarter Financial Results Earnings Call

2016-05-10 08:30:00 | Alexza to Cancel 2016 First Quarter Financial Results Earnings Call

2016-05-10 06:15:22 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material

2016-05-10 03:38:02 | Alexza Pharmaceuticals to be Acquired by Ferrer

2016-05-10 03:30:00 | Alexza Pharmaceuticals to be Acquired by Ferrer

2016-04-29 17:39:15 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits

2016-04-27 16:27:34 | Alexza to Report 2016 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 11, 2016

2016-04-27 16:15:00 | Alexza to Report 2016 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 11, 2016

2016-04-15 17:18:58 | ALEXZA PHARMACEUTICALS INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements an

2016-03-30 13:04:55 | Alexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: Q4, 2015 By the Numbers

2016-03-30 11:47:41 | Alexza Pharmaceuticals, Inc. :ALXA-US: Earnings Analysis: 2015 By the Numbers

2016-03-28 16:22:36 | Alexza Reports Fourth Quarter and Year End 2015 Financial Results

2015-12-24 09:30:02 | New Strong Buy Stocks for December 24th